Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions

• Verfasst von: Eisele, Philipp [VerfasserIn]
• Verfasst von: Wittayer, Matthias Sebastian [VerfasserIn]
• Verfasst von: Weber, Claudia Ellen [VerfasserIn]
• Verfasst von: Platten, Michael [VerfasserIn]
• Verfasst von: Schirmer, Lucas [VerfasserIn]
• Verfasst von: Gass, Achim [VerfasserIn]
• Titel: Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
• Titelzusatz: short report
• Verf.angabe: Philipp Eisele, Matthias Wittayer, Claudia E Weber, Michael Platten, Lucas Schirmer and Achim Gass
• E-Jahr: 2022
• Jahr: December 2022
• Umfang: 5 S.
• Fussnoten: Online veröffentlicht: 1. Juli 2022 ; Gesehen am 30.05.2023
• Titel Quelle: Enthalten in: Multiple sclerosis journal
• Ort Quelle: London : Sage, 1995
• Jahr Quelle: 2022
• Band/Heft Quelle: 28(2022), 14 vom: Dez., Seite 2294-2298
• ISSN Quelle: 1477-0970
• DOI: doi:10.1177/13524585221106338
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1846916909

Abstract

We investigated the impact of disease-modifying therapies (DMTs) on the evolving tissue damage in iron rim multiple sclerosis lesions using a novel post-processing magnetic resonance imaging (MRI) approach, the T1/T2 ratio. In this study, on baseline and 1-year follow-up, T1/T2 ratios of iron rim lesions (IRLs) in patients starting DMT (dimethyl fumarate, fingolimod, ocrelizumab) did not statistically differ compared to patients without DMT. At the second follow-up, T1/T2 ratios were significantly lower in IRLs in patients without DMT (p = 0.002), suggesting that DMTs have a beneficial delayed effect on lesion evolution and tissue matrix damage in IRLs.